Burning Rock Biotech (FRA:6BU0) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6BU0 Burning Rock Biotech Ltd FRA:6BU0
59 GF Score
Price €12.00
GF Value €8.94
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Burning Rock Biotech Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Burning Rock Biotech Quality Rank Related Terms

FRA:6BU0
59GF Score
Burning Rock Biotech Ltd FRA:6BU0
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?

Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued. The current stock price of €12.00 is trading 34.2% above its estimated GF Value™ of €8.94. GuruFocus considers Burning Rock Biotech to be Significantly Overvalued.

Key valuation signals for FRA:6BU0:

  • Quality Rank:
  • GF Value™: €8.94 vs. price of €12.00 (34.2% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Burning Rock Biotech Business Description

Other Exchanges BNR:USA
Address No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a China-based cancer diagnostics company that develops and commercializes next-generation sequencing (NGS) tests for precision oncology. Its central laboratory business provides therapy selection and genomic profiling tests, including products such as OncoScreen and Pan-HEME, to hospitals, physicians, and patients seeking to match cancer patients with targeted therapies and immunotherapies. The company also operates an in-hospital business, partnering with hospitals to establish and run their own NGS testing laboratories, and a pharma research and development services segment that offers companion diagnostics development, biomarker discovery, and clinical trial testing to pharmaceutical and biotechnology companies. Revenue is generated primarily through the central laboratory testing services, supplemented by in-hospital collaborations and pharma service agreements. Burning Rock serves customers across China, with its operations concentrated in the domestic market.
59GF Score

Get the complete analysis for FRA:6BU0

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.00
Price
€8.94
GF Value